{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:10:49Z","timestamp":1792858249007,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bayer (Schweiz) AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40123-025-01239-3","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:54:54Z","timestamp":1758272094000},"page":"2819-2829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Early Outcome Analysis of Intravitreal Aflibercept 8\u00a0mg Treatment in Na\u00efve Patients with Neovascular Age-Related Macular Degeneration Using Artificial Intelligence"],"prefix":"10.1007","volume":"14","author":[{"given":"Nicol\u00f2","family":"Bartolomeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannic Pannatier","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Nascimbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Gallo","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Crozat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Path\u00e9","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"2","key":"1239_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et\u00a0al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"1239_CR2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/J.AJPATH.2012.06.006","volume":"181","author":"LA Kim","year":"2012","unstructured":"Kim LA, D\u2019Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol. 2012;181(2):376. https:\/\/doi.org\/10.1016\/J.AJPATH.2012.06.006.","journal-title":"Am J Pathol"},{"issue":"4","key":"1239_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/J.AJO.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(4):725-731.e1. https:\/\/doi.org\/10.1016\/J.AJO.2015.06.023.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1239_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/S12325-020-01236-X","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, et\u00a0al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR\u202f: a randomized controlled trial. Adv Ther. 2020;37(3):1173\u201387. https:\/\/doi.org\/10.1007\/S12325-020-01236-X.","journal-title":"Adv Ther"},{"issue":"1","key":"1239_CR5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/S12325-019-01147-6\/TABLES\/3","volume":"37","author":"J Carrasco","year":"2020","unstructured":"Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J. Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies. Adv Ther. 2020;37(1):300\u201315. https:\/\/doi.org\/10.1007\/S12325-019-01147-6\/TABLES\/3.","journal-title":"Adv Ther"},{"issue":"11","key":"1239_CR6","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","volume":"121","author":"AC Ho","year":"2014","unstructured":"Ho AC, Busbee BG, Regillo CD, et\u00a0al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181\u201392. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.009.","journal-title":"Ophthalmology"},{"issue":"5","key":"1239_CR7","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/PHARMACEUTICS15051416","volume":"15","author":"D Veritti","year":"2023","unstructured":"Veritti D, Sarao V, Di Bin F, Lanzetta P. Pharmacokinetic and pharmacodynamic rationale for extending VEGF inhibition increasing intravitreal aflibercept dose. Pharmaceutics. 2023;15(5):1416. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15051416.","journal-title":"Pharmaceutics"},{"issue":"9","key":"1239_CR8","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/JAMAOPHTHALMOL.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, et\u00a0al. Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141(9):834\u201342. https:\/\/doi.org\/10.1001\/JAMAOPHTHALMOL.2023.2421.","journal-title":"JAMA Ophthalmol"},{"issue":"10432","key":"1239_CR9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, et\u00a0al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1.","journal-title":"Lancet"},{"issue":"10432","key":"1239_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, et\u00a0al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403(10432):1153\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(23)02577-1.","journal-title":"Lancet"},{"key":"1239_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/S40942-025-00665-6","author":"J Cattaneo","year":"2025","unstructured":"Cattaneo J, De Oliveira Figueiredo EC, Montesel A, Vermeirsch S, Eandi CM. Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-na\u00efve neovascular AMD: AI-assisted fluid volume analysis. Int J Retina Vitreous. 2025. https:\/\/doi.org\/10.1186\/S40942-025-00665-6.","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"1239_CR12","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1136\/BMJOPHTH-2024-002091","volume":"10","author":"D Sambhara","year":"2025","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA. Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol. 2025;10(1):2091. https:\/\/doi.org\/10.1136\/BMJOPHTH-2024-002091.","journal-title":"BMJ Open Ophthalmol"},{"issue":"11","key":"1239_CR13","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/S41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy U, Havilio M, Syntosi A, et\u00a0al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye. 2021;35(11):2983. https:\/\/doi.org\/10.1038\/S41433-020-01354-4.","journal-title":"Eye"},{"issue":"1","key":"1239_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-18158-z","volume":"12","author":"JH Kim","year":"2022","unstructured":"Kim JH, Sagong M, Woo SJ, et\u00a0al. A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea. Sci Rep. 2022;12(1):1\u201313. https:\/\/doi.org\/10.1038\/s41598-022-18158-z.","journal-title":"Sci Rep"},{"issue":"6","key":"1239_CR15","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/IAE.0000000000003023","volume":"41","author":"GS Reiter","year":"2021","unstructured":"Reiter GS, Grechenig C, Vogl WD, et\u00a0al. Analysis of fluid volume and its impact on visual acuity in the fluid study as quantifies with deep learning. Retina. 2021;41(6):1318\u201328. https:\/\/doi.org\/10.1097\/IAE.0000000000003023.","journal-title":"Retina"},{"issue":"1","key":"1239_CR16","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1111\/AOS.15219","volume":"101","author":"M Schranz","year":"2023","unstructured":"Schranz M, Told R, Hacker V, et\u00a0al. Correlation of vascular and fluid-related parameters in neovascular age-related macular degeneration using deep learning. Acta Ophthalmol. 2023;101(1):e95\u2013105. https:\/\/doi.org\/10.1111\/AOS.15219.","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"1239_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.oret.2023.02.008","volume":"7","author":"K Xue","year":"2023","unstructured":"Xue K, Hua P, Maguire MG, et\u00a0al. Prediction for 2-year vision outcomes using early morphologic and functional responses in the comparison of age-related macular degeneration treatments trials. Ophthalmol Retina. 2023;7(7):564\u201372. https:\/\/doi.org\/10.1016\/j.oret.2023.02.008.","journal-title":"Ophthalmol Retina"},{"key":"1239_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/25158414221083363\/","author":"GS Reiter","year":"2022","unstructured":"Reiter GS, Schmidt-Erfurth U. Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy. Ther Adv Ophthalmol. 2022. https:\/\/doi.org\/10.1177\/25158414221083363\/.","journal-title":"Ther Adv Ophthalmol."},{"issue":"1","key":"1239_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/S40942-024-00549-1","volume":"10","author":"V Mares","year":"2024","unstructured":"Mares V, Nehemy MB, Bogunovic H, Frank S, Reiter GS, Schmidt-Erfurth U. AI-based support for optical coherence tomography in age-related macular degeneration. Int J Retina Vitreous. 2024;10(1):31. https:\/\/doi.org\/10.1186\/S40942-024-00549-1.","journal-title":"Int J Retina Vitreous"},{"issue":"8","key":"1239_CR20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/S00417-012-1928-5","volume":"250","author":"Y Akagi-Kurashige","year":"2012","unstructured":"Akagi-Kurashige Y, Tsujikawa A, Oishi A, et\u00a0al. Relationship between retinal morphological findings and visual function in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012;250(8):1129\u201336. https:\/\/doi.org\/10.1007\/S00417-012-1928-5.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1239_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-1-4614-0631-0_6","volume":"723","author":"W Ma","year":"2012","unstructured":"Ma W, Zhao L, Wong WT. Microglia in the outer retina and their relevance to pathogenesis of age-related macular degeneration (AMD). Adv Exp Med Biol. 2012;723:37. https:\/\/doi.org\/10.1007\/978-1-4614-0631-0_6.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"1239_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/S00417-019-04546-1\/","volume":"258","author":"Y Hsia","year":"2020","unstructured":"Hsia Y, Yang CH, Hsieh YT, Yang CM, Ho TC, Lai TT. Hyperreflective foci in predicting the treatment outcome of antivascular endothelial growth factor in neovascular age-related macular degeneration. Graefe\u2019s Arch Clin Exp Ophthalmol. 2020;258(2):273\u201380. https:\/\/doi.org\/10.1007\/S00417-019-04546-1\/.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01239-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01239-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01239-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:41:43Z","timestamp":1760715703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01239-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1239"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01239-3","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aude Ambresin: consultant for Bayer, Novartis, Roche, Apellis and Earlysight; lecturer fees from Optovue, Abbvie, Novartis, Bayer, Roche, Apellis, Astellas and RetinAi\u200b. Nicol\u00f2 Bartolomeo, Yannic Pannatier Schuetz, Anna Chiara Nascimbeni, Daniela Gallo Castro, Baptiste Crozat and Mamadou Path\u00e9 Barry have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study design was approved by the local ethics committee (Commission cantonale d'\u00e9thique de la recherche sur l'\u00eatre humain CER-VD -part of Swissethics) for data collection and analysis (CERVD: 2024\u201301491) and was conducted in accordance with the Declaration of Helsinki. Clinical trial no.: not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}